Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

774.68 -7.70 (-0.98%)
Streaming Delayed Price Updated: 10:29 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
49 50 Next >
News headline image
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Is Regeneron Stock a Buy After a Regulatory Blow? ↗
Don't write this company's eulogy too fast. 
Via The Motley Fool
News headline image
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... 
Via Benzinga
News headline image
Is Regeneron's Stock in Trouble After This FDA Rejection? ↗
The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue. 
Via The Motley Fool
News headline image
Biotech Blues: Stay Balanced Through July Earnings Season ↗
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Regeneron Pharmaceuticals Stock Dipped This Week ↗
A key regulatory setback is weighing on the biotech's stock. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy In July ↗
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
News headline image
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review ↗
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
News headline image
What Will Amgen Buy Next? ↗
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
News headline image
Why Catalent Stock Flopped Today ↗
The company takes the fall for a failed drug application. 
Via The Motley Fool
News headline image
Why Regeneron Stock Is Trading Lower Today ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License... 
Via Benzinga
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Where Regeneron Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023 ↗
 
Via Benzinga
News headline image
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%... 
Via Benzinga
News headline image
18 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Why Regeneron Stock Is Falling Today ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of... 
Via Benzinga
News headline image
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
News headline image
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead ↗
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
News headline image
Biotech And Healthcare Stocks Lagging ↗
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
News headline image
How to Retire Rich: Biotech Stocks Edition ↗
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
News headline image
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
News headline image
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 ↗
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and  
Via Benzinga
News headline image
2 Stocks to Buy No Matter What Happens in June and Beyond ↗
A lot could go wrong in the next few months, but investors should largely ignore all that noise. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.